PrecivityAD2, a blood test to aid Alzheimer's evaluation, is available in 2026 for adults 40 and older with cognitive symptoms including mild cognitive impairment. Access requires a clinician order, costs depend on insurance and assistance, and results guide follow-up about confirmation, treatment options, and care planning.
Mild cognitive impairment means memory or thinking changes that are noticeable but do not remove independence. PrecivityAD2 does not screen healthy adults and does not give a standalone diagnosis. It estimates amyloid likelihood to help a clinician decide what to do next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Is Eligible for Testing?
- What Does the Score Measure?
- How Do You Get Access?
- What Will It Cost in 2026?
- What Should You Ask After Results?
Who Is Eligible for Testing?
Patient Care Online reported the Aug. 20, 2026 FDA clearance for adults 40 and older with signs or symptoms of cognitive impairment in the FDA clearance report. The clearance covers aid to evaluation, not routine checkups.
People with mild cognitive impairment fall inside that symptomatic group. The test is ordered alongside medical history, physical exam, and cognitive testing. A clinician experienced in cognitive impairment must place the order. Asymptomatic adults should not expect coverage or use under this clearance.
What Does the Score Measure?
PrecivityAD2 uses mass spectrometry to measure two blood ratios, Aβ42/40 and p-tau217/np-tau217. The lab combines them into an Amyloid Probability Score 2 from 0 to 100. A higher score means higher likelihood of brain amyloid. In 1,142 symptomatic participants compared with amyloid PET or spinal-fluid markers, a positive result had 97.6% positive predictive value.
A negative result had 93.1% negative predictive value, while 17.3% of results were called likely positive with 77.3% predictive value. The middle group matters for readers with mild cognitive impairment. A likely-positive result does not settle the question. Your clinician may advise PET imaging, spinal-fluid testing, repeat assessment, or watchful follow-up.
How Do You Get Access?
Access starts with the clinician who is already evaluating memory concerns. Patient Care Online reports that the FDA-cleared kit was expected later in 2026 while the CLIA lab version stayed available. Ask the clinic which version it uses and how samples are sent.
Bring a medication list, prior brain scans, and notes on symptom timing. Bring a family member when possible to describe daily changes. Clear records reduce delays in interpretation.
- See a provider experienced in cognitive impairment for symptoms review
- Complete history, exam, and cognitive testing as part of evaluation
- Discuss why the clinician recommends PrecivityAD2 and how results change care
- Confirm the order, sample collection site, and how results will arrive
What Will It Cost in 2026?
Coverage is expanding but remains plan-specific. C2N Diagnostics announced medical-policy coverage for eligible Anthem Blue Cross and Blue Shield members starting Oct. 1, 2026 in the Anthem coverage announcement. The company described it as the first such U.S. insurer policy.
Medicare has no national coverage policy for these FDA-cleared blood tests. HealthcareOnTime notes that asymptomatic screening is not covered. People with mild cognitive impairment should verify plan coverage and prior authorization before blood draw. PrecivityAD lists income-based help for balances over $50 and a six-month interest-free payment plan in the financial assistance guide. Applications are due within 30 days after the first bill. Ask billing for the current application form and deadline in writing.
What Should You Ask After Results?
PrecivityAD2 is not a screening test or standalone diagnosis. Key follow-up is whether PET or spinal-fluid confirmation is needed.
Also ask about treatment eligibility, safety planning, and support services. Write down the score category, next test dates, and who will explain changes. Keep one contact for results, referrals, and billing questions.
- Does my score need PET or spinal-fluid confirmation?
- Do results affect eligibility for Alzheimer's treatments or trials?
- What care plan, driving, work, and home-safety steps fit now?
- When should we repeat cognitive testing or see a specialist?
You Might Also Like
- Subjective Cognitive Decline Data for Public Health Action in 2026: Data Questions Adults in Midlife Should Ask
- Dementia Subtype Data Gaps Identified by NIA in 2026: What Researchers Still Need to Learn for Adults With Memory Concerns
- NIA’s 2026 Late-Life Depression and Dementia Workshop: What Researchers Still Need to Learn for Adults With Memory Concerns
